Centiva Capital’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Centiva Capital’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-426,937	Closed	-$4.62M	–	2398
2023 Q3	$4.62M	Hold	426,937	–	–	0.1%	176
2023 Q2	$4.55M	Buy	426,937 +329,521	+338%	+$3.47M	0.1%	212
2023 Q1	$1.02M	Hold	97,416	–	–	0.03%	612
2022 Q4	$1M	Hold	97,416	–	–	0.03%	568
2022 Q3	$979K	Sell	97,416 -5,834	-6%	-$58.4K	0.02%	629
2022 Q2	$1.04M	Buy	103,250 +3,250	+3%	+$32.3K	0.02%	596
2022 Q1	$988K	Buy	+100,000	New	+$987K	0.02%	712

Centiva Capital's BIOS Position: Q4 2023 in Review

Centiva Capital sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 426,937 shares — an estimated $4.62M sold.

Centiva Capital first reported a position in BIOS in Q1 2022 and held it in 7 quarters. The position peaked at $4.62M in Q3 2023. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

Centiva Capital reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Centiva Capital sold 426,937 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $4.62M.
Centiva Capital first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 7 quarters.
Centiva Capital's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $4.62M in Q3 2023.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.